8-K: Applied Therapeutics Reports Q2 Loss, Advances CMT-SORD Program

Applied Therapeutics, Inc. reported a significant net loss in the second quarter of 2025, alongside positive clinical advancements for its lead drug candidate govorestat in rare diseases and strategic corporate developments.

Summary

• Reported a net loss of $21.3 million for the second quarter of 2025, a significant shift from a net income of $2.9 million in the second quarter of 2024.
• Cash and cash equivalents decreased to $30.4 million as of June 30, 2025, from $79.4 million at December 31, 2024.
• A meeting is scheduled with the FDA in Q3 2025 to discuss the New Drug Application (NDA) submission strategy for govorestat for the treatment of CMT-SORD.
• Presented positive full 12-month clinical results and new topline 18and 24-month data from the INSPIRE Phase 2/3 trial of govorestat for CMT-SORD, highlighting statistically significant improvements in key secondary endpoints and slowed disease progression via MRI at 24 months.
• Launched a sponsored Urine Sorbitol Assay in July 2025 to support the identification of CMT-SORD patients at no cost to healthcare providers.
• Entered into an out-licensing agreement with Biossil, Inc. for AT-001, receiving an upfront payment and eligibility for future royalties and milestone payments.
• Promoted Evan Bailey, M.D., to Chief Medical Officer and Dottie Caplan to Executive Vice President, Patient Advocacy and Government Affairs in June 2025.

Sentiment

Score: 4

Explanation: While there is significant positive clinical and strategic progress, particularly with govorestat for CMT-SORD and the out-licensing deal, the substantial net loss and rapid cash burn raise concerns about the company's financial stability and future funding needs.

Positives

• An FDA meeting is scheduled for Q3 2025 to discuss the NDA submission for govorestat in CMT-SORD, indicating significant regulatory progress.
• Positive clinical data from the INSPIRE Phase 2/3 trial for govorestat in CMT-SORD demonstrated statistically significant improvements in key endpoints (CMT-HI, 10MWRT, CMT-FOM Lower Limb) and slowed disease progression via MRI at 24 months.
• The launch of a no-cost sponsored Urine Sorbitol Assay will facilitate CMT-SORD diagnosis, removing barriers for patients.
• An out-licensing agreement for AT-001 with Biossil, Inc. provides an upfront payment and potential future royalties and milestones, offering a non-dilutive funding source.
• Strategic leadership promotions strengthen the company's clinical development and patient advocacy functions.
• The net loss for the six months ended June 30, 2025, was $43.155 million, an improvement compared to the $81.040 million net loss for the six months ended June 30, 2024.
• Warrant liabilities decreased from $6.314 million at December 31, 2024, to $1.773 million at June 30, 2025.

Negatives

• The company shifted from a net income of $2.9 million in Q2 2024 to a net loss of $21.3 million in Q2 2025.
• Cash and cash equivalents significantly decreased from $79.4 million at December 31, 2024, to $30.4 million at June 30, 2025, indicating a high cash burn rate.
• General and Administrative expenses increased by approximately $2.6 million in Q2 2025 compared to Q2 2024.
• The positive impact from the change in fair value of warrant liabilities, which significantly contributed to Q2 2024 net income ($22.744 million), was much smaller in Q2 2025 ($1.437 million), contributing to the net loss swing.

Risks

• Plans to develop, market, and commercialize product candidates.
• Initiation, timing, progress, and results of current and future preclinical studies and clinical trials and research and development programs.
• Ability to take advantage of expedited regulatory pathways for any product candidates.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.
• Ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies.
• Ability to maintain and establish collaborations or obtain additional funding.
• Ability to obtain and timing of regulatory approval of current and future product candidates.
• Anticipated indications for product candidates, if approved.
• Expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates.
• Ability to fund working capital requirements and expectations regarding the sufficiency of capital resources.
• Implementation of business model and strategic plans for business and product candidates.
• Intellectual property position and the duration of patent rights.
• Developments or disputes concerning intellectual property or other proprietary rights.
• Expectations regarding government and third-party payor coverage and reimbursement.
• Ability to compete in the markets served.
• Impact of government laws and regulations and liabilities thereunder.
• Developments relating to competitors and the industry.
• Ability to achieve the anticipated benefits from agreements entered into in connection with the partnership with Advanz Pharma.
• Other factors that may impact financial results.

Future Outlook

The company is positioned for forward momentum, with a meeting scheduled with the FDA in Q3 2025 to discuss a potential NDA submission for govorestat for CMT-SORD. Management's unwavering priority is transforming the lives of patients with rare diseases, specifically CMT-SORD, Classic Galactosemia, and PMM2-CDG, with a focus on regulatory alignment across the pipeline. New data on govorestat for PMM2-CDG will be presented at the 2025 ASHG Annual Meeting in October.

Management Comments

• "The first half of 2025 has been marked by a period of important execution as we’ve strengthened our internal clinical operations and made significant progress in addressing priorities while aligning on future planning across our pipeline."
• "We are positioned for forward momentum as we engage with the FDA in the third quarter regarding a potential NDA submission for govorestat for the treatment of CMT-SORD."
• "Our commitment to the CMT-SORD community is highlighted by our newly launched sponsored sorbitol assay, which is available to healthcare providers for patients at no-cost, removing potential barriers to diagnosis and treatment."
• "As we look to the remainder of the year, we are focused on regulatory alignment across our pipeline."
• "Our unwavering priority continues to be transforming the lives of patients with rare diseases, specifically CMT-SORD, Classic Galactosemia and PMM2-CDG."

Industry Context

Applied Therapeutics operates in the highly specialized and high-risk, high-reward rare disease biopharmaceutical sector. The focus on orphan drug designations for conditions like CMT-SORD, Classic Galactosemia, and PMM2-CDG aligns with a growing industry trend of targeting underserved patient populations, which can offer expedited regulatory pathways and premium pricing upon approval. The out-licensing of AT-001 for Diabetic Cardiomyopathy suggests a strategic focus on core rare disease assets while monetizing non-core programs, a common practice for clinical-stage biotechs to manage cash burn and focus resources.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's financial performance or clinical trial outcomes against global benchmarks.
• The clinical progress for govorestat in CMT-SORD, particularly the statistically significant improvements and slowed disease progression observed via MRI, suggests promising efficacy data for a rare disease therapeutic, which is a critical factor for success in this industry.
• The shift to a net loss and significant cash burn are common for clinical-stage biopharmaceutical companies that have not yet commercialized products, but the rate of cash depletion warrants close monitoring compared to peers with similar pipeline stages and funding.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value if govorestat gains regulatory approval and commercial success, but current financial losses and cash burn pose dilution risk from future capital raises.
• Patients (CMT-SORD, PMM2-CDG, Classic Galactosemia): Positive impact due to continued clinical development of govorestat, potential for new treatment options, and improved diagnostic access (Urine Sorbitol Assay).
• Healthcare Providers: Benefit from the no-cost Urine Sorbitol Assay to aid in CMT-SORD diagnosis.
• Employees: Positive impact from leadership promotions and continued clinical progress, but financial challenges could pose long-term uncertainty.
• Biossil, Inc.: Gained exclusive worldwide rights to develop and commercialize AT-001, potentially expanding their pipeline.

Next Steps

• Meeting with the FDA in Q3 2025 to discuss NDA submission strategy for govorestat for CMT-SORD.
• Presentation of new data on govorestat for PMM2-CDG at the 2025 ASHG Annual Meeting (October 14-18, 2025).
• Ongoing evaluation of response to the Complete Response Letter (CRL) for govorestat in Classic Galactosemia.
• Continued focus on regulatory alignment across the pipeline.

Key Dates

Recommendation

While Applied Therapeutics has demonstrated significant clinical progress with govorestat, particularly for CMT-SORD, and has made strategic moves like the AT-001 out-licensing, the company's financial performance in Q2 2025 is concerning. The shift from net income to a substantial net loss and the rapid depletion of cash reserves from $79.4 million to $30.4 million in six months indicate a high burn rate and potential need for future capital raises, which could dilute existing shareholders. The positive clinical data provides a strong foundation, but the financial headwinds suggest a 'hold' position until there is clearer visibility on the path to profitability or sustainable funding, balancing the promising pipeline against the immediate financial risks.

Keywords

Applied Therapeutics, APLT, Biopharmaceutical, Rare Diseases, CMT-SORD, Charcot-Marie-Tooth, Govorestat, Aldose Reductase Inhibitor, ARI, Classic Galactosemia, PMM2-CDG, Orphan Drug, Clinical Trial, Phase 2/3, NDA Submission, FDA, Financial Results, Biotech, Drug Development, Sorbitol Dehydrogenase Deficiency, Diabetic Cardiomyopathy, AT-001, Out-licensing